The utilisation of international consensus definitions of the disease polytrauma: a systematic review.

Eur J Trauma Emerg SurgSep 29, 2026 (epub)
Clinical ResearchEmergency MedicineGeneral Surgery

See Yoon Kim, Zhengchao Xu, Zsolt J Balogh

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the uptake of the Newcastle and Berlin consensus definitions of polytrauma in studies published from 2015 to 2025. Out of 2354 studies screened, only 88 met the criteria, with 10 studies (11.4%) using the Berlin definition and 6 studies (6.8%) using the Newcastle definition. The definitions were most frequently reported in 2024.

Key findings

  • Only 11.4% of studies utilized the Berlin definition of polytrauma.
  • 6.8% of studies reported using the Newcastle definition.
  • The consensus definitions were most reported in 2024, with 2 Newcastle and 3 Berlin studies.

Why it matters

Understanding the adoption of standardized definitions for polytrauma is crucial for improving communication and research consistency in emergency medicine and trauma care, ultimately impacting patient outcomes.

Source

PubMed · PMID 42809110

Published in Eur J Trauma Emerg Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.